BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
346.39
+4.59 (1.34%)
At close: Sep 8, 2025, 4:00 PM
346.45
+0.06 (0.02%)
After-hours: Sep 8, 2025, 4:00 PM EDT
BeOne Medicines AG Employees
BeOne Medicines AG had 11,000 employees as of December 31, 2024. The number of employees increased by 400 or 3.77% compared to the previous year.
Employees
11,000
Change (1Y)
400
Growth (1Y)
3.77%
Revenue / Employee
$414,727
Profits / Employee
-$16,149
Market Cap
38.11B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11,000 | 400 | 3.77% |
Dec 31, 2023 | 10,600 | 1,600 | 17.78% |
Dec 31, 2022 | 9,000 | 1,000 | 12.50% |
Dec 31, 2021 | 8,000 | 2,700 | 50.94% |
Dec 31, 2020 | 5,300 | 1,800 | 51.43% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ONC News
- 10 days ago - BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients - Benzinga
- 10 days ago - BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) - Business Wire
- 12 days ago - European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 - Business Wire
- 13 days ago - BeOne Medicines: Brukinsa's Leadership And Royalty Sale Signal A Stronger Future - Seeking Alpha
- 13 days ago - BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - Business Wire
- 14 days ago - BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million - Business Wire
- 18 days ago - European Commission Approves Tablet Formulation of BeOne Medicines' BRUKINSA® for All Approved Indications - Business Wire
- 4 weeks ago - BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript - Seeking Alpha